• - WCCT
  • The Intelligent Trial: AI Comes To Clinical Trials
  • ACT Oncology - Powerful Clinical Research Meets …

As an early phase CRO, WCCT offers clinical support services, state-of-the-art Phase 1 units and research sites, clinical trial and data management.

Powerful Clinical Research Meets Innovation

All Numbered Sessions Listing - The American Society …

Advocacy News & Analysis | ASCO
San Francisco, California, April 5, 2016 – InCarda Therapeutics, Inc. (InCarda), a privately-held biopharmaceutical company focused on the development of therapies for cardiovascular conditions via the inhalation route, today announced that the company has appointed Luiz Belardinelli, M.D., to the position of Chief Medical Officer. Dr. Belardinelli joins InCarda for this position half-time and plans to also continue in his role at Gilead Sciences where he serves as a Senior Advisor for the Cardiovascular Therapeutic Area of Gilead. Previously Luiz was Senior Vice President for Cardiovascular Therapeutics for Gilead. He brings highly relevant cardiovascular experience having been a major contributor to the discovery and development of three cardiovascular products, Adenocard, Lexiscan and Ranexa. “We are thrilled to have Dr. Belardinelli join our team. As a recognized global expert in cardiac arrhythmias (such as atrial fibrillation) we will benefit from his preclinical and clinical knowledge and regulatory experience—both in the U.S. and abroad—as well as his vast network of colleagues in this space,” stated Grace E. Colon, Ph.D., President and Chief Executive Officer of InCarda. “Dr. Belardinelli joins us at an important time, as we are on track to initiate a Phase 1 clinical trial in Q2 of this year to evaluate our inhaled formulation of flecainide for treatment of patients with recent onset paroxysmal atrial fibrillation.”

The USC Westside Center for Diabetes

Please enter your e-mail address to sign up for updates or to access your subscriber preferences.
According to a study by the Journal of the American Medical Informatics Association, clinical trial alerts (CTAs) generated by the EHRs aid in prospective clinical trial patient recruitment (12).Social media, online patient communities, and mobile technologies are other cutting-edge e-recruitment tools used now (Figure 6).


Clinical Research Careers: Reports from a NHLBI …

The Huntsman Cancer Institute mission is to understand cancer from its beginnings, to use that knowledge in the creation and improvement of cancer treatments, to relieve the suffering of cancer patients, and to provide education about cancer risk, prevention, and care.
Huntsman Cancer Institute is a world leader in the study of cancer genetics and manages the Utah Population Database, the largest genetic database in the world, with more than 16 million records linked to genealogies, health records, and vital statistics. Our researchers discovered genes responsible for breast and ovarian cancer(BRCA1 and BRCA2), colon cancer (APC), head and neck cancers (SDH5), and melanoma (p16). We continually develop new approaches to help patients live longer and better lives. With an average of 200 clinical trials open for enrollment at a given time, Huntsman Cancer Institute offers the latest in cancer treatment to patients, some of whom may have few remaining options. Since 1998, we have provided cancer education and outreach to residents of all 50 states and all continents (except Antarctica), with a particular emphasis on underserved Native Americans in our region.
Located at the University of Utah in Salt Lake City, Huntsman Cancer Institute is the only National Cancer Institute-Designated Comprehensive Cancer Center in the Intermountain West, serving the largest geographic area in the country.

Of the approximately 120 adult and pediatric clinical trials open to participation each year, the CTU enters an average of 300 new patients while continuing to follow thousands of participants in long-term follow up. Clinical research conducted at CCMB incorporates studies offered through cooperative groups, pharmaceutical companies and in-house research. Patients participating in these studies have access to some of the most innovative and cutting edge treatments, tests or prevention tools available.

Nearly 37 million people are living with HIV around the world

As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey is dedicated to improving the prevention, detection, treatment, and care of patients with cancer, through the transformation of laboratory discoveries into clinical practice and precision care. Rutgers Cancer Institute delivers advanced comprehensive care to adults and children, including access to clinical trials, and conducts cutting-edge cancer research. The leadership of Rutgers Cancer Institute comprises distinguished researchers and physicians who are internationally recognized in their field. Our basic scientists, clinical researchers, and population scientists meet regularly to exchange information to ensure: that laboratory discoveries are refined and applied to clinical care as quickly as possible; that clinical observations reach laboratory researchers on a continuing basis; and that prevention strategies are interwoven in to all research programs.